Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 5/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.30 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664725 | 0.84 | BACE1 (0.35) | ACHEBACE1 | |
| SCHEMBL16664021 | 0.80 | MAPT (0.36) | ACHEBACE1SCN9AALDH1A1NPSR1 | |
| SCHEMBL15606156 | 0.79 | BACE1 (0.43) | BACE1 | |
| SCHEMBL15549057 | 0.77 | BACE1 (0.35) | ACHEBACE1 | |
| SCHEMBL15606153 | 0.76 | BACE1 (0.38) | ACHEBACE1SCN9AALDH1A1AGTR1 | |
| SCHEMBL16664735 | 0.68 | — | — | |
| SCHEMBL16664754 | 0.67 | BACE1 (0.31) | BACE1LTB4R2 | |
| SCHEMBL15606185 | 0.64 | BACE1 (0.44) | BACE1 | |
| SCHEMBL29227010 | 0.59 | BRD4 (0.48) | HTR2CSLC6A4SCN9AALDH1A1 | |
| SCHEMBL4748073 | 0.58 | KMT2A (0.42) | ACHEALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855486-B1 | SPIRO TETRAHYDRO-BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARES TRADING SA (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, BACE2 | ACHE 542/4885HTR2C 2610/4885SLC6A4 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.